Simran

“So, Mike, I guess our understanding is nerve tape, and I think you addressed this in your prepared remarks as well, but nerve tape appears to be used primarily in the breast segment.”

“I'll just ask mine about the pilot program with the FDA, TEMPO. What does TEMPO mean for type 2 non-insulin and pre-diabetes coverage exactly? Can you just elaborate on the kind of evidence development in the TEMPO program for those two indications and, you know, when you could potentially have a pre-diabetes label?”

“Maybe just to start off on gross margin, maybe help me understand, you know, I think we generally view breast as a higher ASP opportunity. So just any additional color that you can provide around what exactly is driving the lower margin profile for breasts?”

“Maybe just to start out, Mike, since the VLA in December 2025, Can you talk about the reaction to it so far from physicians in each segment of the market and payers as well?”

“Maybe just following up with the prior line of questioning around sort of Q4 and, you know, like what this implies for 2026. Shelly, the last time we talked, you mentioned, you know, as we think about 2026, we should be thinking about sequential growth through the year from Q4.”